23andMe's 'Build-a-Baby' Patent Criticised
By BBC,
BBC News [Quotes CGS's Marcy Darnovsky]
| 10. 03. 2013
A US patent for a database that uses DNA testing to tell prospective parents which traits their future offspring may inherit has been criticised by experts.
23andMe says its Family Traits Inheritor Calculator can predict the risk of inheriting specific diseases as well as details such as height, weight, eye colour and even personality.
Couples send the firm a saliva sample to see what their babies might be like.
But critics have called the project "ethically and socially treacherous".
Designer babies
The patent suggests the database could also be used by fertility clinics to find appropriate donors.
But the Mountain View, California-based firm was quick to say this was no longer part of its plan.
"At the time 23andMe filed the patent, there was consideration that the technology could have potential applications for fertility clinics so language specific to the fertility treatment process was included in the patent," it said in a blog post.
"The company never pursued the concepts discussed in the patent beyond our Family Traits Inheritance Calculator, nor do we have any plans to do...
Related Articles
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Hannah Thomasy, The Scientist | 03.15.2024
23andMe’s stock price since late 2020
23andMe, the first-off-the-blocks personal genomics company, has been struggling lately. In October, there were reports of a massive data breach focusing on 999,999 people with Ashkenazi heritage. The company eventually admitted that hackers had gained at least some access to 6.9 million profiles, and suggested that this was due to customers who had reused passwords. Even before news of the huge leak and the PR faux pas that followed, the company’s stock had...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...